• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CAMP4 Therapeutics Corporation - Common Stock (NQ:CAMP)

4.625 -0.065 (-1.39%)
Streaming Delayed Price Updated: 2:54 PM EDT, Mar 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CAMP4 Therapeutics Corporation - Common Stock

News headline image
CAMP4 Appoints Michael MacLean to its Board of Directors
Today 7:00 EDT
Appointment enhances strategic and financial leadership as the Company advances CMP-002 toward a planned first-in-human Phase 1/2 clinical trial for SYNGAP1-related disorder 
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 to Participate in Upcoming Investor Conferences
March 06, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
March 05, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 20, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
December 18, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
December 18, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 12, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 14, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
November 06, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
October 01, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
September 10, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
August 14, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
Sequans Appoints Jason W. Cohenour to Board of Directors
June 30, 2025
Paris, France--(Newsfile Corp. - June 30, 2025) - Sequans Communications S.A. (NYSE: SQNS), a leading innovator in cellular IoT semiconductor... 
Via Newsfile
News headline image
CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American
May 16, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
May 13, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
April 28, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
March 27, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Appoints Multiple Industry Veterans to its Board of Directors
March 18, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 to Participate in Upcoming Investor Conferences
February 06, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 13, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones
January 07, 2025
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors
December 10, 2024
Industry veterans John Maraganore, Ph.D., and Rachel Meyers, Ph.D., to provide strategic guidance on the company’s RNA Actuating platform to develop a new class of RNA medicines that upregulate protein... 
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference
December 02, 2024
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Reports Third Quarter 2024 Financial Results
November 21, 2024
From CAMP4 Therapeutics
Via GlobeNewswire
News headline image
CAMP4 Announces Pricing of Initial Public Offering
October 10, 2024
From CAMP4 Therapeutics
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap